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ABSTRACT 
The teaching of performance enhancing drugs in U.S. schools and colleges of pharmacy 
is necessary to better help patients who are athletes especially those who compete in 
high-level athletics such as the Olympics or the National Collegiate Athletic Association 
(NCAA). There is no master list for banned substances, they differ for each organization 
and have many exceptions. Pharmacists can play a key role in preventing unintentional 
disqualifications of athletes as there are many medications considered performance 
enhancing drugs including some supplements and stimulants. For example, commonly 
used cold medications may contain pseudoephedrine hydrochloride, a banned substance 
in the world of athletics, with both the athlete and the pharmacist unaware of its status. 
The objectives of the study were to determine whether a school or college of pharmacy 
offers any amount of teaching about performance enhancing drugs, the extent of which 
the topic is incorporated into the curriculum, and if the school or college will offer related 
content in the future if not currently. Another objective of the study was to determine 
whether the institutions that the schools and colleges of pharmacy are associated with 
have intercollegiate athletic programs and whether they offer PharmD curriculum that 
includes performance enhancing drugs. A final objective of the study was to determine 
whether different regions of the United States have influence on whether schools or 
colleges of pharmacy offer PharmD curriculum that includes performance enhancing 
drugs. A descriptive, cross-sectional study was used to collect data from 20 different 
schools and colleges of pharmacy. The respondents reported whether their institution 
currently offers a course about or with content relating to performance enhancing drugs. 
 v 
Follow-up questions about the extent of the course in its information and placement in the 
curriculum were also asked. Most respondents reported that their institution does not 
have a course that discusses performance enhancing drugs, nor will they have one in the 
immediate future. This could be improved if the discussion about pharmacist involvement 
in sports pharmacy increases and its benefits become more widely known and 
recognized.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
 
 
TABLE OF CONTENTS 
List of Diagrams and Tables…………………….………………………………………vii 
Appendices……………………………………………………..……………………….viii 
Background………………………………………………………………………………..1
Methods…………………………………………………………………………………..16 
Results…………………………………………………………………..………………..18 
Discussion.……………………………………………….……………………..………..33 
References………………………………………………………………………………..39  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
 
LIST OF DIAGRAMS AND TABLES 
Table 1 Content Areas Covered in Courses…..………………………….……….20 
 
Diagram 1 Map of the Reporting Schools and Colleges of Pharmacy Based on 
Region……………………..……………………………..………………22 
Diagram 2 Map of the Reporting Schools and Colleges of Pharmacy that Indicated 
Content Related to Performance Enhancing Drugs within their PharmD 
Curriculum According to Region………………………………………...23 
Diagram 3 Map of the Reporting Schools and Colleges of Pharmacy that did not 
Indicate Content Related to Performance Enhancing Drugs within their 
PharmD Curriculum According to Region………………………………24 
Diagram 4 Map of the Reporting Schools and Colleges of Pharmacy that Indicated 
Content Related to Performance Enhancing Drugs within their PharmD 
Curriculum and have Intercollegiate Athletic Programs Associated with 
the Main Institution According to Region………………………...……..26 
Diagram 5  Map of the Reporting Schools and Colleges of Pharmacy that did not 
Indicate Content Related to Performance Enhancing Drugs within their 
PharmD Curriculum and have Intercollegiate Athletic Programs 
Associated with the Main Institution According to Region.……………..27 
Diagram 6 Map of the Number of Schools and Colleges of Pharmacy per Region....28 
Diagram 7 Map of the Percentage of Schools and Colleges of Pharmacy per Region 
with Intercollegiate Athletic Programs Associated with the Main 
Institution…………………………………..…………………………….29 
Diagram 8 Map of the Number of Schools and Colleges of Pharmacy per State……30 
Diagram 9 Map of the Number of Schools and College of Pharmacy per State that 
have Intercollegiate Athletic Programs Associated with the Main 
Institution……………………………………………………….………..31 
Table 2 Summary of Regional Maps……………………………...…….………..32 
 viii 
 
 
APPENDICES 
 
Appendix 1
 Survey……………..……………….…..………………………..……...………..42 
 1 
 
 
BACKGROUND 
History and Definitions  
Ergogenic is a term derived from the Greek words ergon (work) and gennan (to 
produce) and means a strategy that enhances work capacity. There are five categories of 
sports ergogenics: nutritional aids, pharmacological aids, physiological aids, 
psychological aids, and mechanical or biomechanical aids. Performance enhancing drugs 
are pharmacological sports ergogenics (Guimaraes-Ferreira et al. 29). They are 
substances used to improve athletic performance and some examples include anabolic 
steroids, human growth hormones, and erythropoietin [(blood doping)] (“Performance-
Enhancing Drug”). They can be grouped into broad categories including increasing 
concentration and alertness; boosting strength, power, and explosiveness; increasing the 
oxygen-carrying capacity of blood; enhancing recovery, recuperation, and reconstitution 
of the athlete; and improving inflammation and pain (Gaffney 151).  
Performance enhancing drugs have been used since ancient times. Norse warriors 
ate hallucinogenic mushrooms before going into battle (Sommers 106). Ancient Olympic 
athletes ate sheep testicles to increase their testosterone levels (Miller 296). The Greek 
physician Galen was recorded prescribing “the rear hooves of an Abyssinian ass, ground 
up, boiled in oil, and flavored with rose hips and rose petals” in order to improve a 
person’s performance (Grasso et al. 161). It is known that athletes used substances from 
plants including hemp, kava, opium, ginseng root, “ma huang” (ephedra), Strychnos nux 
vomica (strychnine tree), and hallucinogenic mushrooms (Miller 296). However, there 
are many consequences of performance enhancing drugs including irreversible 
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androgenic/anabolic effects, toxic hepatitis, withdrawal, dependence, body dysmorphic 
disorder, depression, aggression, the unmasking or acceleration of cancer growth, 
diabetes mellitus, dyslipidemias, cardiomyopathy, and nephrotoxicity (Wick). Some early 
modern performance enhancing drug usage includes a Welsh cyclist, Arthur Linton, who 
died during a race in 1886. He is believed to have taken trimethyl, a stimulant. In 1889, a 
French physician injected himself with extracts from dog and guinea pig testicular fluid 
because he believed it gave him more energy (“A Timeline of Performance-Enhancing 
Drugs in Sports”). Later in 1904, Thomas Hicks overdosed on brandy with strychnine 
and won gold (Miller 296). During World War II, American, British, German, and 
Japanese armed forces took amphetamines to counteract fatigue, elevate mood, and 
increase endurance leading to their use in sports in the 1950s (“Historical Timeline: 
History of Performance Enhancing Drugs in Sports”). 
Anabolic steroids are normally groups of synthetic hormones, which are derived 
from testosterone, and used medically to increase tissue growth. They are abused by 
athletes to increase endurance and the size and strength of muscles (“Anabolic Steroid”). 
They also may increase aggressiveness of the athlete both on and off the field (Gaffney 
153). They are the most commonly abused substances (Wick). Another type of anabolic 
steroids are designer steroids which are very dangerous and designed to be undetectable 
by current drug tests (Mayo Clinic Staff, “Performance-Enhancing Drugs: Know the 
Risks”). In 1958, the U.S. Food and Drug Administration (FDA) approved the first 
anabolic steroid for sale in the United States (“Historical Timeline: History of 
Performance Enhancing Drugs in Sports”). In the 1976 Olympics in Montreal, Canada, 
the East German Olympic team used steroids and evaded detection through the use of 
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state plan theme 14-25. State plan theme 14-25 was a state-sponsored doping program 
under East Germany’s elite sports federation headed by Manfred Ewald and monitored by 
the Ministry of State Security (Stasi). Girls as young as 12 were regularly given untested 
steroids and male hormones as part of their training with side-effects including male-type 
hair growth, deepened voices, liver disease, heart disease, depression, infertility, 
miscarriages, and death. East German athletes were given Oral-Turninabol or O-T which 
was an anabolic steroid derived from testosterone. O-T and other anabolic steroids are 
known to increase muscle mass and quicken recovery time (“Doping for Gold”). 
Human growth hormone, a peptide hormone, is defined as naturally occurring or 
genetically engineered to treat children with growth hormone deficiencies. It has also 
been used by athletes to increase muscle mass (“Human Growth Hormone”). It is 
produced by the pituitary gland and can help regulate body composition, body fluids, 
muscle and bone growth, sugar and fat metabolism, and possibly heart function (Khatri). 
It can also increase exercise capacity, bone density, and muscle mass, but decrease body 
fat. However, there are multiple risks such as increased carpal tunnel syndrome and 
insulin resistance, Type 2 diabetes, edema, joint and muscle pain, gynecomastia, and 
increased risk of certain cancers (Mayo Clinic Staff, “Human Growth Hormone (HGH): 
Does It Slow Aging?”). When produced synthetically it is an active ingredient in many 
prescription drugs and other products. It was developed in 1985 and approved by the 
FDA for specific uses in children and adults. Some of those uses include Turner’s 
syndrome, Prader-Willi syndrome, chronic kidney disease, HGH deficiency or 
insufficiency, children born small for gestational age, short bowl syndrome, and muscle-
wasting disease associated with HIV/AIDS. While used by athletes to improve muscle 
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mass, human growth hormone’s effect on athletic performance is unknown (Khatri).  
Androstenedione (andro) is a hormone produced by the adrenal glands, ovaries, 
and testes. It is converted to testosterone and a form of estrogen (estradiol) in both men 
and women. Andro is legally available as a prescription and is a controlled substance. 
Contrary to scientific studies, manufacturers and bodybuilding magazines claim andro 
allows athletes to train harder and recover faster. Andro can cause acne, diminished 
sperm production, shrinking of the testicles, and enlargement of the breasts in men. In 
women, it can cause acne and maculation. Andro can also cause damage to the heart and 
blood vessels which increases the risk for heart attack and stroke (Mayo Clinic Staff, 
“Performance-Enhancing Drugs: Know the Risks”). 
Doping is illegal and defined as when a substance or technique is used to improve 
athletic performance. Some examples are anabolic steroids and erythropoietin or blood 
doping (“Doping”). Doping comes from the 19th century Dutch word dop which was used 
to describe a South African drink. That drink consisted of an extract of cola nuts, 
xanthines (found in caffeine), and alcohol. The drink was intended to improve endurance 
(Grasso et al. 161). The objectives of doping include increasing strength and endurance, 
aiding in workout/injury recovery, altering intensity and aggression, sharpening focus and 
concentration, combatting exhaustion and fatigue, reducing weight/body fat, relieving 
aches and pains, and increasing muscle mass and/or oxygenation. Doping’s payoff is 
increased oxygen delivery to active muscles which includes an effective technique to 
increase the number of red blood cells (Wick). Erythropoietin is a type of hormone that is 
used to treat anemia in those with severe kidney disease. It causes the increase of red 
blood cells and hemoglobin. Erythropoietin also increases the movement of oxygen to the 
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muscles and can increase the risk of stroke, heart attack, and blockage in an artery in the 
lungs. Epoetin, a synthetic form of erythropoietin, is commonly used by endurance 
athletes (Mayo Clinic Staff, “Performance-Enhancing Drugs: Know the Risks”). 
Performance enhancing supplements are taken instead of or in addition to 
performance enhancing drugs. Many nutritional supplements are available over-the-
counter as powders or pills (Mayo Clinic Staff, “Performance-Enhancing Drugs: Know 
the Risks”). They are often included alongside performance enhancing drugs in resources 
such as “Performance-Enhancing Drugs: Know the Risks” written by Mayo Clinic Staff 
and “Care of the Young Athlete Patient Handouts - Performance-Enhancing 
Supplements” by the American Academy of Pediatrics. In both resources, for example, 
anabolic steroids are discussed near creatine and stimulants. For the purpose of this study 
the term performance enhancing drugs will mainly be used to encompass the supplements 
and stimulants as they are at times on banned substance lists as well.  
Creatine monohydrate is a nutritional supplement that is popular among athletes. 
It is a naturally occurring compound which is produced by the body to help the muscles 
release energy. Scientific research dictates that it may give athletes small gains in short-
term bursts of power. Some possible side effects are stomach cramps, muscle cramps, and 
weight gain. Weight gain is more likely to be water retention than increasing muscle 
mass (Mayo Clinic Staff, “Performance-Enhancing Drugs: Know the Risks”). It is also 
available over-the-counter in different forms and not screened or banned by WADA, the 
IOC, or the NCAA. However, these forms are not regulated by the U.S. Food and Drug 
Administration (FDA) and may contain other substances and/or different amounts of the 
substance (Butts et al.). 
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Performance enhancing stimulants are used to stimulate the central nervous 
system and increase heart rate and blood pressure. Stimulants can increase physical 
performance by improving endurance, reducing fatigue, suppressing appetite, and 
increasing alertness and aggressiveness. They also include caffeine and amphetamines. 
Many cold medicines have the stimulants ephedrine or pseudoephedrine hydrochloride. 
Energy drinks contain high doses of caffeine and other stimulants. Some risks include 
nervousness, insomnia, dehydration, heatstroke, addiction or tolerance, heart problems, 
tremors, and stroke. Also cocaine and methamphetamine are stimulants (Mayo Clinic 
Staff, “Performance-Enhancing Drugs: Know the Risks”). 
Diuretics are used by athletes to help pass drug tests. They are drugs that change 
the body’s natural balance of fluids and salts (electrolytes). They can lead to dehydration. 
The loss of water decreases the athlete’s weight and is used to help pass drug tests as the 
urine is diluted. This is sometimes called a “masking” agent. Some risks include 
dehydration, muscle cramps, dizziness, potassium deficiency, drops in blood pressure, 
loss of coordination and balance, and death (Mayo Clinic Staff, “Performance-Enhancing 
Drugs: Know the Risks”).  
History of Banning and Testing for Drugs 
In 1928, the International Amatueur Athletic Federation (IAAF) was the first 
international sporting federation to ban doping by athletes. In 1967, The International 
Olympic Committee (IOC) established a medical commission to fight doping. There are 
three guiding principles: protection of the health of the athletes, respect for the medical 
and sport ethics, and equality for the competing athletes (“Historical Timeline: History of 
Performance Enhancing Drugs in Sports”). The main goals of the IOC are managing 
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health care and doping control services during the Olympic and Youth Games, giving a 
factual education to athletes and their entourage, developing and promoting the use of 
ethical standards in sports science and medicine, using new technologies to improve 
athletes’ health and prevent potential damaging effects, and promoting health and 
physical activity for the entire population (“Medical and Scientific Commission”). In 
1967, the IOC Medical Commission released a list of banned substances which had 
stimulants and narcotic analgesics including sympathomimetic amines, psychomotor 
stimulants, and miscellaneous central nervous system stimulants including alcohol. In the 
1968 Olympic Games in Mexico City, Mexico, the IOC implemented a regime of 
preliminary drug testing. It was also the first time an athlete was disqualified for drug use 
when Hans-Gunnar Lilienvall, a member of the Swedish modern pentathlon team, caused 
the entire Swedish men’s team to forfeit their bronze medals when his blood alcohol level 
was tested to be higher than the allowable limit. In the 1972 Olympic Games in Munich, 
Germany, the first comprehensive testing at the international competition level took place 
for narcotics and stimulants (“Historical Timeline: History of Performance Enhancing 
Drugs in Sports”). In 1975, anabolic steroids were added to the IOC’s banned substance 
list (“A Timeline of Performance-Enhancing Drugs in Sports”). In 1976, at the Olympic 
Games in Montreal, Canada, anabolic steroids were tested for the first time (“Historical 
Timeline: History of Performance Enhancing Drugs in Sports”). In the 1988 Olympic 
Games in Seoul, South Korea, Ben Johnson, a Jamaican born Canadian sprinter won gold 
against Carl Lewis, but was stripped of his medal three days later after he tested positive 
for anabolic steroids (“Ben Johnson Wins Gold, Temporarily”). Also in 1988, on 
November 18, 1988, President Ronald Regan signed the Anti-Drug Abuse Act of 1988 
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which outlawed the sale of steroids for non-medical purposes. On October 5, 1990, 
Congress passed the Anabolic Steroids Control Act which classified steroids in the same 
legal class as amphetamines, methamphetamines, opium, and morphine. On June 7, 1991, 
Major League Baseball banned all possession, sale, or use of any illegal drug or 
controlled substance including steroids. In 1999, the World Anti-Doping Association 
(WADA) was established and in 2000, the United States Anti-Doping Agency (USADA) 
was established (“Historical Timeline: History of Performance Enhancing Drugs in 
Sports”). WADA is an international independent agency that involves scientific research, 
education, development of anti-doping capacities, and monitoring of anti-doping 
programs around the world (Guimaraes-Ferreira et al. 29). In 2002, the first reported 
designer steroid was found in an athlete’s urine and in 2003, gene doping was banned by 
WADA (“Historical Timeline: History of Performance Enhancing Drugs in Sports”). 
WADA developed the World Anti-Doping Code in 2003. The World Anti-Doping 
Program in sports is based on this Code, a document that “advance[s] the anti-doping 
effort through universal harmonization of core anti-doping elements” (World Anti-
Doping Agency). The code is both specific and flexible depending on the principle and 
focus. The World Anti-Doping Code and the World Anti-Doping Program protect the 
right of athletes to participate in doping-free sport and encourages health, fairness, and 
equality worldwide in athletics. It also attempts to standardize anti-doping programs that 
have effectiveness and are harmoniously coordinated at international and national levels 
in the efforts of anti-doping programs. These programs help to detect, deter, and prevent 
doping (World Anti-Doping Agency). However, there is no universal list of banned 
substances (Ross) and in 2004 the IOC gave WADA control of the prohibited substances 
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list (“Historical Timeline: History of Performance Enhancing Drugs in Sports”). There 
are instead many databases. The NCAA has its own list for college students (Ross) which 
is published annually (Wick). The Olympics and the National Basketball Association 
(NBA) have their own lists. The lists are not identical and have many differences. If a 
student athlete wants to attend the Olympics, they must abide by both the NCAA and the 
Olympics banned substances lists. There are also grey/contradicting circumstances. For 
example, during the Olympics some drugs are banned at all times, while others are 
banned only during the competition (Ross). The National Center for Drug Free Sport 
offers drug-use prevention services for athletic organizations. The Resource Exchange 
Center (REC) educates athletes and other supporting athletic staff on dietary supplement 
labels and assigns risk levels based on where ingredients fall in some banned drug 
classes. Most banned or not-banned substances are in the database (Shaman). It is 
believed 6/10 athletes use and test positive for drugs/anabolic steroids/banned substances 
(Wick).  
Pharmacists in Sports: General Information and History 
 The Statement of Professional Standards: “The Role of the Pharmacist in the 
Fight Against Doping in Sport” was adopted by the International Pharmaceutical 
Federation (FIP) in 2005 and details a need for pharmacists to be involved in sports 
medicine. In 2014, it was transformed into the FIP Guidelines which refers to the World 
Anti-Doping Agency (WADA) Anti-Doping Code. The guidelines also discuss 
recommendations about doping control in regard to pharmacists, governments, and 
pharmaceutical associations (Hooper et al.). Pharmacists are recommended by WADA to 
remain up-to-date with the contents of the WADA Code, assist athletes to recognize if the 
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use of a substance may be banned or restricted in their sport, and provide information to 
athletes about the risks and benefits of nutritional supplements (Hooper et al.), such as 
creatine monohydrate (Guimaraes-Ferreira et al. 32), as many of those supplements 
contain banned substances in violation of the WADA Code or specific sports-governing 
parties (Hooper et al.). Sports pharmacy also includes providing drug-information and 
education services to athletes, coaches, and supporters. Pharmacists could identify, 
manage, and monitor athletes actively seeking performance enhancing supplements. The 
prevention and control of doping has many aspects including drug-use for therapeutics 
and performance enhancement. Pharmacist involvement requires knowledge and 
interpretation of banned substance lists, advising on dietary supplements, over-the-
counter (OTC) and prescription medicines and products, and tailored formulary 
development, inventory control and record keeping. Pharmacists have also been involved 
in drug-testing (Hooper et al.). 
 In Japan, the Japan Pharmaceutical Association and the Japan Anti-Doping 
Agency (JADA) created an initiative in 2009 that promotes anti-doping by using the 
knowledge of many different health professions. Pharmacists can become certified as 
“Sports Pharmacists” by JADA and in 2014 there were 6000 certified (Hooper et al.). 
 In 2012 at the London Olympic Games, more than 100 volunteer pharmacists and 
pharmacy technicians were at the polyclinics within the Athlete Villages. The pharmacy 
services were provided in accordance to United Kingdom Standards. Pharmacists wrote 
and reviewed Olympic and Paralympic drug formularies and delivered international drug 
information service to the prescribers at the Games. Pharmacists also provided services to 
non-athletes at the Games through the Pharmacy Minor Ailments Scheme to decrease the 
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workload on other health professionals. The Center for Pharmacy Postgraduate Education 
(CPPE) created a 12-week online e-learning program titled ‘The Use of Drugs in Sport: A 
Healthcare Professional’s Perspective’ for the 2012 Olympic Games. It had three 
sections: doping and anti-doping in sport, pharmacy services and support in sport and 
fitness, and medical services at international sporting events. Although no longer 
available, this program was a pre-requisite for pharmacy volunteers and was available on 
the CPPE website for all pharmacists, pharmacy technicians, and health professionals in 
the United Kingdom. In 2018, a similar program was created for the Commonwealth 
Games at the Gold Coast in Australia (Hooper et al.). 
 There is limited opportunity for education in sports pharmacy in undergraduate 
curriculum and postgraduate education. Exclusion of sports pharmacy in undergraduate 
curriculum is shown in one study to have only 6% of pharmacists recall being taught 
about doping control while in school and 26% in another study. However, 90% of 
pharmacy students in Qatar were for incorporating sports pharmacy into undergraduate 
curriculum. Pharmacists are interested in short post-graduate/professional development 
courses that are either online or face-to-face in sports pharmacy, but most are unable to 
attend them due to limited opportunity (Hooper et al.). 
Need for Pharmacists in Sports 
While many banned substances are unnecessary and even harmful to athletes, 
many drugs that are banned across the different organizations are everyday and/or 
medically necessary prescriptions. This includes Tylenol and asthma inhalers. There are 
also legitimate medical purposes as to why an athlete may need to take banned substances 
including hypertension, asthma, and hormone replacement therapy. In the 2000 
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Olympics, Andreea Mädälina Räducan, a Romanian gymnast, had pseudoephedrine in 
her system because she had a cold. Pseudoephedrine is a banned substance in the 
Olympics and she was stripped of her medal (Ross). Some athletes are even unaware that 
they are ingesting banned substances in dietary supplements because they are not 
typically listed on the label (Shaman). In 2006, a U.S. skeleton racer was banned for the 
use of hair growth medicine that contained Finasteride which was only on the banned 
substances list from 2005-2009 (“Historical Timeline: History of Performance Enhancing 
Drugs in Sports”). 
Pharmacists provide healthcare to patients in sporting culture in non-
competitive/individual fitness and local club sports and they provide advice for elite 
athletes competing in the Olympic Games or in other international areas. There are roles 
in doping and anti-doping, injury management and prevention, and first aid. A systematic 
review on sports pharmacy has not been performed in the past although there are some 
guidelines for pharmacists about management of common sports injuries and counseling 
or advising athletes. Pharmacists know about prescription medications, over-the-counter 
medications, and many other drugs. They know their side effects, contraindications, 
indications, etc. However, many interact with athletes on a very limited basis, outside of 
their athletic facilities, and have limited knowledge about sports-related medicine and 
drugs making it difficult at times to give evidence-based advice to athletes, coaches and 
managers, clubs and organizations, family members, and supporters. This is in-part due to 
the fact that there is a lack of educational opportunities for pharmacists and pharmacy 
students to learn and practice sports pharmacy. Most pharmacists would also not have 
knowledge about the banned substances lists and the substances on them or the 
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confidence to discuss doping and/or licit and illicit drugs with an athlete (Hooper et al.). 
Ambrose (2008) and Doty et al. (2015) showed that increasing the amount of education 
and opportunities to practice skills in sports pharmacy may increase pharmacist 
knowledge and confidence (qtd. in Hooper et al.). Most collegiate and professional sports 
teams employ athletic trainers and physicians, but few have a pharmacist on staff (“Drugs 
and Sports: New Niche for Pharmacy”). Pharmacists were able to track usage through 
medication management software tools by the late 1990s. In the mid-2000s, steroid and 
doping controversies among baseball players, professional cyclists, and Olympic athletes 
provided incentive for sports teams and medical professionals to track and monitor drug 
usage (Shaman). It was described how “many athletes know the pharmacokinetics and 
pharmacology of the drugs they take better than a third-year pharmacy student does” 
(Wick). Pharmacists need to be more involved in doping prevention and monitoring 
athletes with legitimate medical reasons to why they are ingesting banned substances. 
They need to be able to counsel athletes about dietary supplements that are banned, 
contaminated, or suspicious. Pharmacists need knowledge, background, or insight about 
banned substance lists. They need to encourage athletes to research or to contact the 
associations involved, and they need to encourage athletes to apply for medically 
necessary exceptions (Ross). Most athletes purchase supplements online without 
consulting a health professional. Pharmacists are consulted only between 2% and 35% of 
the time. Athletes also discuss doping with other players, coaches, team managers, and 
the internet rather than a health professional which is a major part of the problem 
(Hooper et al.). 
As of 2018, there are 314,300 pharmacist jobs in the United States (“Pharmacists: 
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Occupational Outlook Handbook”), 143 U.S. schools and colleges of pharmacy (one of 
which is international based) with accredited (full or candidate status) and 1 with 
precandidate status (144 total institutions) (“Programs by State”) are institutional 
members of AACP (“AACP Institutional Membership”), and 112 of those institutions 
have a pharmacy school or college and intercollegiate athletic programs. Medical 
campuses or graduate institutes of a larger university, college, or consortium (i.e. 
University of Arkansas for Medical Sciences and University of Arkansas) are considered 
separate institutions in this regard. Pharmacists are needed in the world of athletics, the 
majority have attended institutions with athletics programs, and may not know an asthma 
inhaler can disqualify an athlete (Ross). 
Curriculum within Pharmacy Schools and Colleges  
The purpose of accreditation is quality assurance. In pharmacy, it allows 
practitioners to create requirements of schools and colleges so that professional students 
are prepared to enter the profession. The Accreditation Council for Pharmacy Education 
(ACPE) provides this accreditation to PharmD Programs (“PharmD Program 
Accreditation”). From basic research, the ACPE does not require PharmD programs to 
teach students out right about performance enhancing drugs in curricular didactic courses. 
The ACPE requires that schools and colleges of pharmacy provide a broad range of 
elective courses. This is in order for students to be able to learn about career options, 
cultivate personal interest, and achieve curricular outcomes (Santee et al.). The ACPE 
does not mandate the specific number of elective credits within PharmD curriculum 
though most programs have between 6 and 15 hours of didactic elective courses and 1 to 
4 elective APPEs (Accreditation Council for Pharmacy Education 7-8). 
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Study Objectives 
 Due to the lack of literature and easily accessible information about the amount of 
teaching schools and colleges of pharmacy across the United States provide about 
performance enhancing drugs, the objectives of this study are to: 
1. To determine whether a school or college of pharmacy offers any amount of 
teaching about performance enhancing drugs. 
2. To determine the extent performance enhancing drugs are incorporated into the 
curriculum of a school or college of pharmacy. 
3. To determine whether a school or college of pharmacy, that currently does not 
offer a course that includes teaching about performance enhancing drugs, will in 
the future.  
4. To determine if different regions of the United States offer pharmacy curricula 
that includes performance enhancing drugs.  
5. To determine whether the institutions that have schools and colleges of pharmacy 
have athletic programs and whether or not they offer a curriculum that includes 
performance enhancing drugs.  
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METHODS 
Design 
 This study employed a cross-sectional, descriptive design to assess study 
objectives using a self-administered electronic survey that was sent to U.S. schools and 
colleges of pharmacy. 
Sample 
A list of curriculum coordinators for United States schools and colleges of 
pharmacy (study participants) were obtained and purchased from the American 
Association of Colleges of Pharmacy (AACP) in June of 2019. The list included 198 
curriculum coordinators. There were 144 schools of pharmacy as of July 2019 
(“Academic Pharmacy’s Vital Statistics”), which indicates there is likely more than one 
curriculum coordinator designated for some schools or colleges of pharmacy. 
Survey Instrument 
The first question in the survey instrument asked the participant what school or 
college of pharmacy they were reporting from, which allowed the researchers to screen 
for duplicate submissions. The second question asked the participant if their school or 
college of pharmacy currently has performance enhancing drugs instruction incorporated 
into their curriculum. If not, respondents were asked to comment on future offerings of 
content related to performance enhancing drugs, before being exited from the survey.  
For those that did indicate offering performance enhancing drugs instruction, 
respondents were asked to indicate how it was offered (required course, elective course, 
entire course, partial course, rotation, etc.). This question branched off into a series of 
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questions asking about course names, contact hours and/or credits of performance 
enhancing drugs coverage, and specific content covered related to performance 
enhancing drugs in these courses. Respondents were given the opportunity to provide 
qualitative comments regarding performance enhancing drugs coverage in their 
respective schools or colleges. 
Data Collection 
 University of Mississippi IRB exemption was obtained for this study before data 
collection commenced. Self-administered surveys were distributed via Qualtrics®. 
Qualtrics® is an internet-based survey company and potential participants were sent an 
invitation to complete a survey over email in September of 2019. The invitation included 
information about the study and a detailed a voluntary link to the survey. The potential 
participants were also informed that their answers were confidential and the name of the 
school or college they represented was only recorded to prevent duplicate data. Potential 
respondents were sent two email invitations with the survey link embedded, one email 
was the initial contact, and the second email was the reminder sent to those who did not 
respond to the initial. Participants were invited to forward the survey to someone in their 
school or college who might have better knowledge of curricular coverage of 
performance enhancing drugs, than the designated curriculum coordinator. 
Analysis  
Simple descriptive statistics were used to tabulate data. 
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RESULTS 
Sample Description and Knowledge of Performance Enhancing Drugs 
To have a better understanding of the characteristics and aspects of the curriculum 
in the respondents’ school or college of pharmacy, several questions were asked in regard 
to the coverage that their institution could possess about performance enhancing drugs. 
Of the 21 completed surveys (10.6% response rate), only 20 were used as one institution 
had two respondents on its behalf. The more complete response from that school or 
college of pharmacy was used in the analysis of the data. Of the 20 responding schools 
only 8 reported that their professional pharmacy program offers content related to 
performance enhancing drugs in their PharmD curriculum. Of the 12 who reported that 
their professional pharmacy program does not offer content related to performance 
enhancing drugs in their PharmD curriculum, only two schools or colleges of pharmacy 
reported that there are future plans for coverage of them. One of the institutions indicated 
that “We discussed this once in our curriculum. However, we [are] planning on including 
this as part of our discussion on hormone therapy (testosterone, etc.) this year. It will 
likely be an added discussion point (15-20 minutes) or incorporated into a case.” 
Embedded in Curriculum 
Respondents could indicate where content related to performance enhancing 
drugs is placed in their PharmD curriculum. Eight schools or colleges of pharmacy 
reported (100%, n=8). 75% (n=8) reported that the content is embedded in a required 
didactic course, 50% (n=8) reported that the content is offered as a stand-alone didactic 
elective course, 12.5% (n=8) reported that the content is embedded in a required 
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introductory or advanced pharmacy practice experience (IPPE or APPE), 0% (n=8) 
reported that the content is provided as an elective introductory or advanced pharmacy 
practice experience (IPPE or APPE), and 12.5% (n=8) reported other, but indicated that 
the content was provided as a lecture in an elective didactic course. 37.5% (n=8) reported 
that content is both embedded in a required didactic course and offered as a stand-alone 
didactic elective course. 12.5% (n=8) reported that content is embedded in a required 
didactic course, offered as a stand-alone didactic elective course, and embedded in a 
required introductory or advanced pharmacy practice experience (IPPE or APPE). 
Contact or Credit Hours 
Respondents could have indicated the number of contact or credit hours 
performance enhancing drugs are incorporated in their PharmD curriculum. Six schools 
or colleges of pharmacy reported (75%, n=8) that content related to performance 
enhancing drugs is embedded in a required didactic course. Five schools or colleges of 
pharmacy responded with the approximate number of contact hours dedicated to 
performance enhancing drugs. Two respondents indicated 1 contact hour, one respondent 
indicated 2 contact hours, one respondent indicated 5 contact hours, and one respondent 
indicated 10 contact hours.  
Of the four schools or colleges of pharmacy that reported (50%, n=8) content 
related to performance enhancing drugs is offered as a stand-alone didactic elective 
course, four responded with the approximate number of credit hours dedicated to 
performance enhancing drugs. One respondent indicated 1.5 credit hours and three 
respondents indicated 2 credit hours.  
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One school or college of pharmacy reported (12.5%, n=8) content related to 
performance enhancing drugs offered in a required introductory or advanced pharmacy 
practice experience (IPPE or APPE). The respondent indicated 5 contact hours occurred 
within the experience.   
Content Covered 
 Respondents could have indicated where the content related to performance 
enhancing drugs is placed in the curriculum. Seven schools or colleges of pharmacy 
reported (87.5%, n=8). 100% (n=7) reported their content is incorporated with 
pharmacology, 71.4% (n=7) reported their content is incorporated with legal 
implications, 71.4% (n=7) reported their content is incorporated with practice 
implications, 28.6% (n=7) reported their content is incorporated with sports 
organizations’ regulations, 57.1% (n=7) reported their content is incorporated with ethical 
considerations, and 14.3% (n=7) reported their content is incorporated with drug testing 
procedures. This table dictates the respondents’ responses in regard to the multiple 
content areas their particular school or college or pharmacy covers in their curriculum. 
 
Additional Responses and Comments  
One of the follow up questions asked pertained to the name of the course with 
content related to performance enhancing drugs. The responses include: PHCY 505: 
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Integrated systems: Musculoskeletal (anabolic steroids), PHCY 506: Integrated systems: 
CNS PSYCH (stimulants), Natural medicines, Integrated Sequence,  Pharmacy Practice I 
Principles of Pharmacology, Physiology III, Integrated Drug Therapy, PHCL 351: Drugs 
and Human Performance, Use and Abuse of Drugs, Prescription drug abuse, and 
Complementary and Alternative Medications. 
Other comments made by respondents regarding their courses that include 
discussions about performance enhancing drugs or the lack of them are: “Only over the 
counter performance enhancing drugs, herbals, etc. are covered.,” “There may be some 
discussion in individual courses and electives, but it has not been specifically mentioned 
as a focus for our curriculum. We would certainly consider this to be content typically 
covered in an elective,” “The elective course in which this lecture is presented is elected 
in the P1 year by 90% or more of students,” “Not noted previously, but also included to 
some degree in law course,” and “Interesting thought.” 
Regional Differences in Offering Performance Enhancing Drug Curricula 
The following three maps were created to determine if different regions of the 
United States offer pharmacy curricula that includes performance enhancing drugs. The 
maps were created using online map development software (“Create Custom Map: 
United States”). The maps are split into the census regions of the United States (US 
Census Bureau). This excludes the territories which are being used as its own entity for 
purpose of these infographics. 
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The reporting schools and colleges of pharmacy (n = 20) are described using the 
key in regard to their location. The Northeast region of the United States includes 20% of 
the respondents, the Midwest region includes 15% of the respondents, the Southern 
region includes 45% of the respondents, and the Western region includes 20% of the 
respondents. The territories that have schools or colleges of pharmacy includes 0% of the 
respondents.  
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The reporting schools and colleges of pharmacy that indicated content related to 
performance enhancing drugs within their respective PharmD curriculum according to 
region are described in this map. The reporting schools and colleges of pharmacy (n=8) 
that indicated content related to performance enhancing drugs within their respective 
PharmD curriculum according to region are 0% in the Northeast region, 12.5% in the 
Midwest region, 50% in the Southern region, and 37.5% in the Western region. *The 
territories that have schools or colleges of pharmacy had 0% of the respondents overall 
within the study and are included in this infographic for visualization and comparison.  
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 The reporting schools and colleges of pharmacy that did not indicate content 
related to performance enhancing drugs within their respective PharmD curriculum 
according to region are described. The reporting schools and colleges of pharmacy 
(n=12) that did not indicate content related to performance enhancing drugs within their 
respective PharmD curriculum according to region are 33.3% in the Northeast region, 
16.7% in the Midwest region, 41.7% in the Southern region, and 8.3% in the Western 
region. *The territories that have schools or colleges of pharmacy had 0% of the 
respondents overall within the study and are included in this infographic for visualization 
and comparison.  
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Regional Differences in Schools or Colleges of Pharmacy with Athletic Programs 
The following six maps were created to determine whether the colleges and 
universities that have schools and colleges of pharmacy have athletic programs and 
whether or not they offer a curriculum that includes performance enhancing drugs. The 
maps were created using online map development software (“Create Custom Map: 
United States”). The first four maps are split into the census regions of the United States 
(US Census Bureau). This excludes the territories which are being used as its own entity 
for purpose of these infographics. 
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The reporting schools and colleges of pharmacy that indicated content related to 
performance enhancing drugs within their respective PharmD curriculum and have 
intercollegiate athletic programs associated with the main institution according to region 
are described. The Midwest region (n=1) has 0% of the reporting schools or colleges or 
pharmacy for that region, the Southern region (n=4) has 100%, the Western region (n=3) 
has 66.7%. *The territories that have schools or colleges of pharmacy had 0% of the 
respondents overall within the study and are included in this infographic for visualization 
and comparison. **The Northeast region has zero reporting schools or colleges of 
pharmacy.  
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The reporting schools and colleges of pharmacy that did not indicated content 
related to performance enhancing drugs within their respective PharmD curriculum and 
have intercollegiate athletic programs according to region associated with the main 
institution are described. The Northeast region (n=4) has 75% of the reporting schools or 
colleges of pharmacy for that region, the Midwest region (n=2) has 50%, the Southern 
region (n=5) has 80%, and the Western region has (n=1) 0%. *The territories that have 
schools or colleges of pharmacy had 0% of the respondents overall within the study and 
are included in this infographic for visualization and comparison.  
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The number of schools and colleges of pharmacy per region are shown. There are 
26 schools and colleges of pharmacy in the Northeast region, 32 in the Midwest region, 
55 in the Southern region, 29 in the Western region, and 1 in an U.S. territory. Also, this 
does not include Lebanese American University or branch campuses across state lines 
(i.e., Albany College of Pharmacy and Health Sciences-Colchester).  
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The percentage of schools and colleges of pharmacy that have intercollegiate 
athletic programs associated with the main institution per region are shown. In the 
Northeast region 84.6% (n=26) of institutions that have a school or college of pharmacy 
have Intercollegiate Athletic programs, in the Midwest region 84.4% (n=32), in the 
Southern region 81.8% (n=55), in the Western region 58.6% (n=29), and in the U.S. 
territories 0% (n=1). This does not include Lebanese American University or branch 
campuses across state lines (i.e., Albany College of Pharmacy and Health Sciences-
Colchester).  
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This map (“Create Custom Map: United States”) indicates the number of schools 
and colleges of pharmacy per state (“AACP Institutional Membership”). It does not 
include Lebanese American University or branch campuses across state lines (i.e., 
Albany College of Pharmacy and Health Sciences-Colchester).  
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This map (“Create Custom Map: United States”) indicates the number of schools 
and colleges of pharmacy per state (“AACP Institutional Membership”) that also have 
intercollegiate athletic programs associated with their respective main institutions. It does 
not include Lebanese American University or branch campuses across state lines (i.e., 
Albany College of Pharmacy and Health Sciences-Colchester). Medical campuses or 
graduate institutes of a larger university, college, or consortium (i.e., University of 
Arkansas for Medical Sciences and University of Arkansas) are also considered separate.  
Of the U.S. States and the District of Columbia, 58% (n=50) of U.S. States, have 
the same number of schools and colleges of pharmacy as the amount of main institutions 
within the state with intercollegiate athletic programs. When compared by region (US 
Census Bureau) the Northeast region has 9 states and 66.7% (n=9) of states in that region 
have the same number of schools and colleges of pharmacy as the amount of main 
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institutions within the state with intercollegiate athletic programs. The Midwest region 
has 12 states and 66.7% (n=12) of states, the Southern region has 16 states and 1 district 
and 52.9% (n=17) of states and a district, and the Western region has 13 states and 76.9% 
(n=13) of states. 
Summary of Regional Maps 
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DISCUSSION 
The discussion of increasing the inclusion of performance enhancing drugs into 
PharmD curriculum at U.S. schools and colleges of pharmacy should occur in the 
immediate future. The number of individuals involved in athletics is increasing and the 
substances included on the banned substance lists of the many different sports 
organizations are ever changing. Therefore, the demand for pharmacists to have 
knowledge and experience with performance enhancing drugs should be increasing. 
Pharmacists can have a positive impact on the world of sports pharmacy if given the 
opportunity to gain important knowledge when enrolled in a school or college of 
pharmacy and/or multiple opportunities for Continuing Educations (CEs) related to the 
subject matter. It is crucial that pharmacy schools and colleges incorporate performance 
enhancing drugs into their curriculum if only to give their students a background to 
increase awareness and potentially help athletes whether novice or high-level. Limited 
studies exist about athletics and pharmacy. The significance of this study was to better 
understand the number of U.S. schools and colleges of pharmacy that teach performance 
enhancing drugs to their students and the extent of which they do so. After analyzing the 
results of this study, it has been determined that while there are some schools and 
colleges of pharmacy that include content related to performance enhancing drugs in their 
curriculum, there are many more that have yet to do so and do not currently have future 
implementation plans.  
Interpretation of Results – Knowledge of Performance Enhancing Drugs 
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 Overall, very few schools or colleges of pharmacy across the country have 
courses that include content related to performance enhancing drugs. Also, while the 
majority of schools and colleges of pharmacy have intercollegiate athletics associated 
with the main institution, very few, according to the data, include content of this subject 
matter. 
Interpretation of Results – Embedded in Curriculum 
 Overall, the majority of the schools and colleges of pharmacy reporting indicated 
that content related to performance enhancing drugs is embedded in a required didactic 
course or offered as a stand-alone didactic elective course. A percentage of the 
respondents indicated that content is both embedded in a required didactic course and 
offered as a stand-alone didactic elective course. Some reported that content is embedded 
in IPPEs or APPEs or as a lecture in an elective didactic course. These findings indicate 
that schools or colleges of pharmacy which have content related to performance 
enhancing drugs embedded in their PharmD curriculum provide at least a background if 
not an entire course of material.  
Interpretation of Results – Contact or Credit Hours 
 Overall, the number of contact hours performance enhancing drugs is taught when 
embedded in required didactic non stand-alone courses with material pertaining to 
performance enhancing drugs is very low and ranges from 1 – 10 contact hours in total. 
The number of credit hours for a stand-alone didactic elective course however is overall 
between 1.5 or 2, with the majority of respondents indicating 2 which seems average as 
the elective would not be required by ACPE and elective hours are decided upon by the 
school of college or pharmacy itself. One school did indicate that there is content related 
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to performance enhancing drugs in an IPPE or APPE for approximately 5 contact hours 
within the experience which as schools or colleges of pharmacy provide multiple IPPEs 
and APPEs over the course of a pharmacy student’s four years, this is very minimal time 
and only makes up a very small percentage of a pharmacy student’s practical experience 
time.  
Interpretation of Results – Content Covered 
Overall, the content covered in regard to performance enhancing drugs differs per 
school or college of pharmacy with one commonality, pharmacology. Practice 
implications and legal implications are the next two most common content covered in 
addition to pharmacology. The respondents’ schools or colleges of pharmacy covered at 
least two content areas. Two institutions cover five out of the 6 content areas asked. The 
content areas asked in the survey were pharmacology, legal implications, practice 
implications, sports organizations’ regulations, ethical considerations, and drug testing 
procedures as these are the most inclusive areas involved in performance enhancing 
drugs. Other areas could have been asked, but that is a limitation of the study.   
Interpretation of Results - Regional Differences in Curricula 
 The highest percentage of responses came from the Southern region of the United 
States. This is consistent with the proportion of schools and colleges of pharmacy in the 
Southern region, as indicated on the map on page 28 of this document. While the 
Southern region was more likely to indicate including content related to performance 
enhancing drugs within their respective PharmD curriculum, they were also more likely 
not to include this content. These results may likely be a function of the higher response 
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rate from the Southern region, although the response rate is consistent with the higher 
number of pharmacy schools or colleges in the Southern region. 
Interpretation of Results - Athletic Programs 
 While the Southern region more often indicated having content related to 
performance enhancing drugs within an institution’s PharmD curriculum and have 
intercollegiate athletic programs associated with the main institution, they were also more 
likely to indicate not to. Causal relationships cannot be drawn given the descriptive study 
design employed. The results indicated this may be a function of the higher, but 
proportionately appropriate rate of response from the Southern region. However, when 
looking at the number of pharmacy schools and colleges in the U.S. that are associated 
with a main institution that has an athletic program in general, a higher proportion is 
found in the Northeast region. Further research is needed to explore the relationship 
between the teaching of performance enhancing drugs in a pharmacy program and 
athletic programs. There is little doubt that athletic programs can contribute to the 
teaching of performance enhancing drugs in a school or college of pharmacy. 
Limitations  
 Given the topic of this research and the way the data had to be collected, the 
greatest limitation to the results of this study was the response rate. Schools and colleges 
of pharmacy curriculum coordinators, administers, and professors are extremely busy 
year-round and may not have had the time to respond to the survey. Some might have 
been unsure who to forward the survey email to, some might not have seen the survey 
email, and others might have had the survey email go directly into their spam inbox. 
Another limitation may have been the lack of discussion of performance enhancing 
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supplements or stimulants within the survey or the introduction to the survey. Both were 
instead included under the title performance enhancing drugs without enough regard to 
knowledge level. A second limitation involving the survey included not specifying more 
content areas that could potentially have been covered by the courses. Given the low 
response rate, results should be interpreted with caution and cannot be generalized to 
pharmacy schools or colleges throughout the country. 
Future Research  
This study focused solely on whether U.S. schools and colleges of pharmacy 
taught content related to performance enhancing drugs by surveying their curricular 
coordinators. Future research could expand on these findings and determine whether 
students at different schools and colleges of pharmacy would be interested in learning 
about the subject. This could also potentially influence the addition of performance 
enhancing drugs into the PharmD curriculum. Future research could also be done, as 
previously stated, on the relationship between the teaching of performance enhancing 
drugs in a pharmacy program and athletic programs. 
Study Implications 
 Although there are few schools or colleges of pharmacy who offer courses about 
performance enhancing drugs, the findings of the study indicate that institutions may not 
realize the benefit of such courses due to the lack of current relevant information or of a 
true job market in the United States for sports pharmacists. As the majority of institutions 
with schools or colleges of pharmacy have intercollegiate athletic programs associated 
with the main institution, but do not offer courses with content about performance 
enhancing drugs it is evident that the students are not taught such content that pertains to 
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the immediate vicinity. Also, to increase pharmacist involvement in sports, athletes need 
to be aware that pharmacists are the drug experts and can help meet difficult organization 
guidelines. 
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APPENDIX 1: SURVEY 
 
Dear Curriculum Coordinator: 
  
My name is Sara D. Green, and I am a rising first-year pharmacy student at The 
University of Mississippi. I am asking for your participation in a research survey that I 
am conducting through the Sally McDonnell Barksdale Honors College. This survey 
should take no more than 5-6 minutes of your time. It includes various questions about 
your curricular coverage of performance enhancing drugs in your professional program 
(PharmD). If you would like to forward this survey on to someone in your school more 
knowledgeable about this topic, please feel free to do so. Your willingness to participate 
in this research will help me better understand the depth of knowledge that students in 
pharmacy schools have about performance enhancing drugs. 
  
Please keep in mind that your participation in this survey is entirely voluntary. Your 
responses will remain confidential. The purpose of asking the school for which you are 
reporting in the survey is to ensure that there are no duplicates for your school. Data will 
be reported in aggregate only, and no school names will be reported. 
 
This study has been reviewed by the University of Mississippi’s Institutional Review 
Board (IRB). If you have any questions, please contact the IRB at (662) 915-7482. 
  
If you have any questions about the research project specifically, feel free to contact me 
at sdgreen1@go.olemiss.edu, or my advisor, Dr. Erin Holmes, at erholmes@olemiss.edu, 
or (662) 915-5914.  
  
Thank you in advance for your participation. 
  
Sincerely,  
Sara D. Green 
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